Special Issue Editor
Dr. Şerife Mehlika Kuşkonmaz
Ankara Training and Research Hospital, Department of Endocrinology and Metabolism
Diabetes treatment and side effects of antidiabetic medications, disorders of parathyroid, pituitary diseases.
Dr. Şerife Mehlika Kuşkonmaz was born in 1975 in Ankara. She was graduated from Hacettepe University Faculty of Medicine at 1999. She trained in Internal Medicine and in Endocrinology and Metabolism at Hacettepe University Hospital between 2000-2008. She worked in different medical centers as a specialist in the field of endocrinology, including Başkent University Hospital and Güven Hospital. Dr. Kuşkonmaz is now working as an associate professor in Ankara Research and Training Hospital Department of Endocrinology and Metabolism.
Important Discussions on SGLT2 Inhibitor
This special series of reviews focuses on the newest class of SGLT2 inhibitors.
Sodium-glucose transporter 2 (SGLT2) inhibitors are also called Gliflozins. These prevent the reabsorption of glucose from the blood that’s filtered through your kidneys, therefore facilitating glucose excretion in the urine. This helps reduce your blood sugar levels.
Sodium-Glucose Transport Protein 2 (SGLT2) inhibitors are also called Gliflozins. These prevent the reabsorption of glucose from the blood that’s filtered through your kidneys, therefore facilitating glucose excretion in the urine. This helps reduce your blood sugar levels.
To date, the U.S. Food and Drug Administration (FDA) has approved four types of SGLT2 inhibitors to treat type 2 diabetes:
- SGLT2 (Sodium Glucose Transporter 2) Inhibitors
- Blood Sugar
- Diabetes Mellitus
- Type II Diabetes
- Glucose in Blood
- Body Weight
- Blood Pressure
- Dual Therapy
- Diabetic Ketoacidosis
- Diuretic Effects